Systemic Sclerosis (SSc) Clinical Trials

43 recruiting

Systemic Sclerosis (SSc) Trials at a Glance

43 actively recruiting trials for systemic sclerosis (ssc) are listed on ClinicalTrialsFinder across 6 cities in 33 countries. The largest study group is Phase 1 with 16 trials, with the heaviest enrollment activity in Hangzhou, London, and Ann Arbor. Lead sponsors running systemic sclerosis (ssc) studies include Hacettepe University, Beijing GoBroad Hospital, and The Children's Hospital of Zhejiang University School of Medicine.

Browse systemic sclerosis (ssc) trials by phase

Treatments under study

About Systemic Sclerosis (SSc) Clinical Trials

Looking for clinical trials for Systemic Sclerosis (SSc)? There are currently 43 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Systemic Sclerosis (SSc) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Systemic Sclerosis (SSc) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 43 trials

Recruiting
Phase 1

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)Lupus Nephritis+2 more
Fate Therapeutics244 enrolled18 locationsNCT06308978
Recruiting
Phase 2

A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

Systemic Sclerosis (SSc)
argenx81 enrolled74 locationsNCT06655155
Recruiting
Phase 4

Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases

Psoriatic Arthritis (PsA)Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)+9 more
University of Sao Paulo General Hospital477 enrolled2 locationsNCT07087912
Recruiting
Early Phase 1

MTS109 in Patients With Refractory Autoimmune Diseases

Systemic Lupus ErythematosusIdiopathic Inflammatory MyopathiesSystemic Sclerosis (SSc)
Shanghai Changzheng Hospital15 enrolled1 locationNCT07526350
Recruiting
Phase 1Phase 2

Controlling Hyperactive Immunity With Long-lived Lymphocytes

Rheumatoid Arthritis (RA)Autoimmune Rheumatologic DiseaseDiffuse Cutaneous Systemic Sclerosis+1 more
Quell Therapeutics Limited16 enrolled6 locationsNCT07473154
Recruiting
Early Phase 1

Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07507201
Recruiting
Not Applicable

Systemic Sclerosis DIet for GastrointESTinal Symptoms

Systemic Sclerosis (SSc)
University of Michigan60 enrolled1 locationNCT07402226
Recruiting

Assessment of Nutritional Status in Rheumatic Diseases and Association to Disease Activity

Psoriatic Arthritis (PsA)Systemic Sclerosis (SSc)Spondyloarthritis (SpA)+1 more
Cairo University460 enrolled1 locationNCT07277491
Recruiting
Phase 1

CT1190B in the Treatment of Patients With Moderate to Severe Refractory Systemic Lupus Erythematosus (SLE) or Refractory/Progressive Systemic Sclerosis (SSc)

Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)
Beijing GoBroad Hospital27 enrolled1 locationNCT06822881
Recruiting
Phase 1

A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)Inflammatory Myopathy+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07104721
Recruiting

Quantification of Calcinosis Cutis Disease Burden Using Computed Tomography Images

Systemic Sclerosis (SSc)Calcinosis Cutis
Yale University56 enrolled1 locationNCT07228429
Recruiting
Phase 2

Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)

SclerodermaSystemic Sclerosis (SSc)
Zura Bio Inc80 enrolled51 locationsNCT06843239
Recruiting
Phase 1

A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Inflammatory MyopathySystemic Sclerosis (SSc)+2 more
Therorna12 enrolled1 locationNCT07413341
Recruiting
Phase 1

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07305116
Recruiting
Not Applicable

Safety and Efficacy of Adipose-Derived Regenerative Cells (ADRCs) for Improving Hand Dysfunction in Systemic Sclerosis

Systemic Sclerosis (SSc)Hand Dysfunction
Cytori Therapeutics48 enrolled2 locationsNCT07360808
Recruiting
Not Applicable

The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life

Systemic Sclerosis (SSc)
Robyn T. Domsic, MD, MPH160 enrolled4 locationsNCT06675344
Recruiting
Phase 2

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

Systemic Sclerosis (SSc)Refractory Rheumatoid Arthritis (RA)Idiopathic Inflammatory Myopathies (IIMs)
Artiva Biotherapeutics, Inc.90 enrolled26 locationsNCT06991114
Recruiting
Not Applicable

Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases

Systemic Lupus ErythematosusSjogren's SyndromeSystemic Sclerosis (SSc)+3 more
Second Affiliated Hospital, School of Medicine, Zhejiang University15 enrolled1 locationNCT06614270
Recruiting
Phase 1

Clinical Study of CD19 CAR-T in the Treatment of Refractory Systemic Sclerosis

Systemic Sclerosis (SSc)
The Children's Hospital of Zhejiang University School of Medicine12 enrolled2 locationsNCT06792344
Recruiting
Phase 3

Topical Cannabidiol Lotion for Pruritus Relief in Scleroderma

Intervention StudySystemic Sclerosis (SSc)Mediciine
Khon Kaen University36 enrolled1 locationNCT07245238